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Results: Ninety-ﬁve patients were included in this study. Seventy ﬁve 
underwent EPP, 9 P/D, and 11 P. Of these 95 patients with ﬁnal diag-
nosis of MPM, 80 (84.3%) were classiﬁed as epithelial and 15 (15.7%) 
as biphasic. Among the 87 patients classiﬁed as MPM of epithelial type 
after the initial thoracoscopy procedure, 75 (86.2%) were conﬁrmed as 
a true histological diagnosis and 12 (13.7%) were found to be biphasic 
at ﬁnal diagnosis. One patient with a biphasic type at initial diagnostic 
procedure was found as epithelial type after surgical histological as-
sessment. The sensitivity and speciﬁcity values of epithelial diagnosis 
after thoracoscopy were 94 % and 25 %, respectively, with a positive 
predictive value of 86 % and a negative predictive value of 37 %. At 
contrary, the sensitivity and speciﬁcity values of biphasic diagnosis 
after thoracoscopy were 20 % and 98 %, respectively, with a positive 
predictive value of 75 % and a negative predictive value of 87 %.
Conclusions: Thoracoscopy pleural biopsy is conﬁrmed as the cor-
nerstone for the diagnosis of MPM. However this procedure is less 
efﬁcient in diagnosing histological type as epithelial versus biphasic 
subtype.
P1-122 Mesothelioma and Other Thoracic Malignancy Posters, Mon, Sept 3 
Thymic neuroendocrine tumors: report of 8 cases
Margery, Jacques1 Rufﬁe, Pierre2 Magois, Eline1 Saint Blancard, 
Patrick1 Duvillard, Pierre2 Baudin, Eric2 Guigay, Joel2 
1 Percy Armed Forces Hospital, Clamart, France 2 Institut Gustave 
Roussy, Villejuif, France 
Background: Thymic neuroendocrine tumors (TNET) are rare neo-
plasms. We report the clinical and pathological features of 8 TNET.
Results: There were 2 women and 6 men (mean age of 54.5 years), 
presenting with local symptoms (cough, dyspnea, thoracic pain) in 4 
cases, bone metastases in 1 case and Cushing syndrome in 2 cases. 
One patient was diagnosed incidentally. None of them had history of 
MEN. The tumors were divided according to histopathologic features 
into high-grade (n=7) and low-grade (n=1) types. Staging revealed 
two stages I, three stages II, one stage III and two stages IV tumors. 
Six patients underwent surgery and complete excision was possible 
in 3 cases. Five patients had received postoperative radiotherapy. Six 
patients had received chemotherapy (at ﬁrst to fourth lines). Follow-up 
was available in all patients. Three patients died of distant metastasis 
(at 13 and 52 months). Three patients are alive with disease (at 73 and 
103 months) and two are alive and disease-free (at 10 and 81 months).
Conclusions: Patients with TNET are considered to have a worse 
prognosis than patients with pulmonary carcinoid. According to the 
5 years-survival (>50%) in our study, prognosis may be better than 
reported in the literature. 
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Background: There is little published data on chemotherapy in pul-
monary carcinoid tumors. The objective of this retrospective study is 
to evaluate the response rates to different chemotherapy regimens in 
atypical pulmonary carcinoid patients.
Methods: Patients with pulmonary neuroendocrine tumors treated at 
our institution were identiﬁed. The medical records of patients with 
conﬁrmed diagnosis of atypical pulmonary carcinoid were reviewed for 
the presence of progressive disease, treatment with chemotherapy, and 
response to this treatment. 
Results: 37 pts with progressive atypical pulmonary carcinoid tumor 
who were treated with chemotherapy were identiﬁed. Of these, 2 
patients received induction chemotherapy with cisplatin and etoposide 
(PE) before surgery, to which one had a partial response and the other 
had stable disease. One patient with unresectable pulmonary carcinoid 
tumor progressed under PE regimen. 
34 metastatic patients (liver or bone metastasis) received various 
ﬁrst-line chemotherapy regimens: 17 patients were treated with 5-FU 
and streptozotocin-based regimen (FS), 9 patients with PE-based 
chemotherapy, and 8 patients with other associations combining 5-FU 
or doxorubicin. There were overall 11 partial responses (PR), 11 stable 
disease (SD), and 12 progressive disease (PD). 
The overall response rate to ﬁrst-line chemotherapy was 32%. FS com-
bination resulted in 6/17 PR (35%) and 5/17 SD (29%). PE regimen 
resulted in 3/12 PR (25%) and 4/12 SD (33%) in the whole population, 
2/9 PR (22%) and 3/9 SD (33%) in metastatic patients. 
22 patients received a second-line chemotherapy resulting in 2 PR, one 
PR to 5-FU and dacarbazine regimen, the other to FS combination; 10 
patients achieved a SD of whom 5 were treated with FS-based regimen 
and 4 with 5-FU drug. 3 PE regimen resulted in PD. 7 patients received 
a third-line chemotherapy resulting in 1 PR to 5-FU and 3 SD under 
1 FS association, 1 5-FU and dacarbazine regimen, and 1 dacarbazine 
and interferon combination. Prolonged stable disease were observed 
and 4 patients then could receive chemoembolization.
Conclusion: This retrospective review of 37 patients with atypi-
cal pulmonary carcinoid tumors shows a response rate to ﬁrst-line 
chemotherapy of 32%. More objective responses and prolonged stable 
diseases were observed in metastatic patients treated with 5-FU and 
streptozotocin-based regimen.
P1-124 Mesothelioma and Other Thoracic Malignancy Posters, Mon, Sept 3 
Malignant mesothelioma: prognosis not as bad as generally 
believed
Hillerdal, Gunnar1 Sorensen, Jens-Benn2 Sundstrom, Stein3 Riska, 
Henrik4 Vikstrom, Anders5 
1 Karolinska Hospital, Stockholm, Sweden 2 National University 
Hospital, Copenhagen, Copenhagen, Denmark 3 Regional Hospital, 
Trondheim, Trondheim, Norway 4 Helsinki University Hospital (HUS), 
Helsinki, Finland 5 Linkoping Universitry Hospital, Linkoping, Sweden 
Introduction: It is generally considered that survival in malignant 
mesothelioma is less than one year. In the largest study so far on the 
disease, the Pemetrexed Study in the US, where 448 patients were 
randomized to either Pemetrexed + Cisplatin or to Cisplatin alone, the 
survival in the Pemetrexed arm was 12 months versus 9 months in the 
cisplatin arm alone. Many other studies have come to similar results. 
However, the experience of the Nordic Mesothelioma Groups is differ-
ent We here present some data from the last study, where 184 patients 
with malignant mesothelioma, all stages, PS 0-2, all ages, were treated 
with a combination of Liposomized Doxorubicine, Carboplatin, and 
Gemcitabine.
